ICPT
Intercept Pharmaceuticals Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
Market Cap: 794 Million
Primary Exchange: NASDAQ
Website: interceptpharma.com
Shares Outstanding: 41.8 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.0
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 2793 trading days
From: 2014-03-14 To: 2023-11-07
Lowest Point:
Intercept up 4% from intraday low as RBC defends
via: SeekingAlpha at 2019-06-13 11:59:43:000
Intercept Pharmaceuticals ( ICPT +0.6% ) has rebounded from the session low of $78.21 on the heels of bullish comments from RBC that recent concerns with the potential FDA nod for obeticholic acid in NASH are unfounded. More news on: Intercept Pharmaceuticals, Inc., Healthcare stocks new… read more...
Merck And Private Partner NGM Hope For Once-Monthly Dosing NASH Drug
via: SeekingAlpha at 2019-06-11 15:33:43:000
Merck (MRK) and its partner NGM Biopharmaceuticals hope to deliver on a potential treatment for non-alcoholic steatohepatitis and type 2 diabetes. This is what both companies showed when some preliminary data was released for a study using MK-3655 to treat patients with non-alcoholic fatty l… read more...
Merck And Private Partner NGM Hope For Once-Monthly Dosing NASH Drug
via: SeekingAlpha at 2019-06-11 15:33:43:000
Merck (MRK) and its partner NGM Biopharmaceuticals hope to deliver on a potential treatment for non-alcoholic steatohepatitis and type 2 diabetes. This is what both companies showed when some preliminary data was released for a study using MK-3655 to treat patients with non-alcoholic fatty l… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|